Evaluation of the immune response in BALB/c mice induced by a novel DNA vaccine expressing GRA14 against Toxoplasma gondii
E. Ahmadpour
Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
Search for more papers by this authorS. Sarvi
Toxoplasmosis Research Center, Mazandaran University of Medical Sciences, Sari, Iran
Search for more papers by this authorM. B. Hashemi Soteh
Molecular and Cell Biology Research Center, Mazandaran University of Medical Sciences, Sari, Iran
Search for more papers by this authorM. Sharif
Toxoplasmosis Research Center, Mazandaran University of Medical Sciences, Sari, Iran
Search for more papers by this authorM. T. Rahimi
School of Medicine, Shahroud University of Medical Sciences, Shahroud, Iran
Search for more papers by this authorR. Valadan
Molecular and Cell Biology Research Center, Mazandaran University of Medical Sciences, Sari, Iran
Search for more papers by this authorM. Tehrani
Molecular and Cell Biology Research Center, Mazandaran University of Medical Sciences, Sari, Iran
Search for more papers by this authorA. Khalilian
Biostatistics Department, Mazandaran University of Medical Sciences, Sari, Iran
Search for more papers by this authorM. Montazeri
Toxoplasmosis Research Center, Mazandaran University of Medical Sciences, Sari, Iran
Search for more papers by this authorCorresponding Author
A. Daryani
Toxoplasmosis Research Center, Mazandaran University of Medical Sciences, Sari, Iran
Correspondence
Ahmad Daryani, Department of Parasitology and Mycology, Sari Medical School, Mazandaran University of Medical Sciences, Sari, Iran.
Email: [email protected]
Search for more papers by this authorE. Ahmadpour
Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
Search for more papers by this authorS. Sarvi
Toxoplasmosis Research Center, Mazandaran University of Medical Sciences, Sari, Iran
Search for more papers by this authorM. B. Hashemi Soteh
Molecular and Cell Biology Research Center, Mazandaran University of Medical Sciences, Sari, Iran
Search for more papers by this authorM. Sharif
Toxoplasmosis Research Center, Mazandaran University of Medical Sciences, Sari, Iran
Search for more papers by this authorM. T. Rahimi
School of Medicine, Shahroud University of Medical Sciences, Shahroud, Iran
Search for more papers by this authorR. Valadan
Molecular and Cell Biology Research Center, Mazandaran University of Medical Sciences, Sari, Iran
Search for more papers by this authorM. Tehrani
Molecular and Cell Biology Research Center, Mazandaran University of Medical Sciences, Sari, Iran
Search for more papers by this authorA. Khalilian
Biostatistics Department, Mazandaran University of Medical Sciences, Sari, Iran
Search for more papers by this authorM. Montazeri
Toxoplasmosis Research Center, Mazandaran University of Medical Sciences, Sari, Iran
Search for more papers by this authorCorresponding Author
A. Daryani
Toxoplasmosis Research Center, Mazandaran University of Medical Sciences, Sari, Iran
Correspondence
Ahmad Daryani, Department of Parasitology and Mycology, Sari Medical School, Mazandaran University of Medical Sciences, Sari, Iran.
Email: [email protected]
Search for more papers by this authorSummary
Toxoplasma gondii can cause severe and even fatal disease in human beings and animals. Effective vaccines may contribute to control toxoplasmosis. GRA14, a novel secreted dense granule protein of T. gondii, has been proposed as a vaccine candidate due to its intervacuolar transport and unique topology in the parasitophorous vacuole membrane. In this study, we constructed a DNA vaccine encoding GRA14 of T. gondii. BALB/c mice were immunized intramuscularly three times at 2 week intervals and challenged with T. gondii RH strain 5 weeks later. The immune responses were evaluated using lymphocyte proliferation assay, cytokine and antibody measurements. In addition, the survival times and parasite load of mice challenged with the virulent T. gondii RH strain were evaluated. The results showed that the mice immunized with pcGRA14 induced both enhanced specific humoral and Th1 cellular immune responses, and also mice immunized with the pcGRA14 showed an increased survival time and decreased parasite load compared with control groups (P<.05). The results indicated, for the first time, that the GRA14 is a potential DNA vaccine against toxoplasmosis.
References
- 1Weiss LM, Dubey JP. Toxoplasmosis: a history of clinical observations. Int J Parasitol. 2009; 39: 895-901.
- 2Ahmadpour E, Daryani A, Sharif M, et al. Toxoplasmosis in immunocompromised patients in Iran: a systematic review and meta-analysis. J Infect Dev Ctries. 2014; 8: 1503-1510.
- 3Montoya JG, Liesenfeld O. Toxoplasmosis. Lancet. 2004; 363: 1965-1976.
- 4Foroutan-Rad M, Majidiani H, Dalvand S, et al. Toxoplasmosis in blood donors: a systematic review and meta-analysis. Transfus Med Rev. 2016; 30: 116-122.
- 5Hill D, Dubey JP. Toxoplasma gondii: transmission, diagnosis and prevention. Clin Microbiol Infect. 2002; 8: 634-640.
- 6Lopes-Mori FM, Mitsuka-Bregano R, Capobiango JD, et al. Programs for control of congenital toxoplasmosis. Rev Assoc Med Bras. 2011; 57: 594-599.
- 7Rajapakse S, Chrishan Shivanthan M, Samaranayake N, Rodrigo C, Deepika Fernando S. Antibiotics for human toxoplasmosis: a systematic review of randomized trials. Pathog Glob Health. 2013; 107: 162-169.
- 8Montazeri M, Daryani A, Ebrahimzadeh M, Ahmadpour E, Sharif M, Sarvi S. Effect of propranolol alone and in combination with pyrimethamine on acute murine toxoplasmosis. Jundishapur J Microbiol. 2015; 8: e22572-e22577.
- 9Hiszczynska-Sawicka E, Gatkowska JM, Grzybowski MM, Dlugonska H. Veterinary vaccines against toxoplasmosis. Parasitology. 2014; 141: 1365-1378.
- 10Zhang NZ, Chen J, Wang M, Petersen E, Zhu XQ. Vaccines against Toxoplasma gondii: new developments and perspectives. Expert Rev Vaccines. 2013; 12: 1287-1299.
- 11Falcon J, Freyre A. Toxoplasma gondii: prototype immunization of lambs against formation of muscle and brain cysts. Vet Parasitol. 2009; 166: 15-20.
- 12Waldeland H, Frenkel JK. Live and killed vaccines against toxoplasmosis in mice. J Parasitol. 1983; 69: 60-65.
- 13Lin A, Lu S, Chen C, et al. [The protective effect against Toxoplasma infection in mice immunized with laser-irradiated Toxoplasma tachyzoites]. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi. 1999; 17: 387-389.
- 14Costa-Silva TA, Meira CS, Ferreira IM, Hiramoto RM, Pereira-Chioccola VL. Evaluation of immunization with tachyzoite excreted-secreted proteins in a novel susceptible mouse model (A/Sn) for Toxoplasma gondii. Exp Parasitol. 2008; 120: 227-234.
- 15Daryani A, Sharif M, Dadimoghaddam Y, et al. Determination of parasitic load in different tissues of murine toxoplasmosis after immunization by excretory-secretory antigens using Real time QPCR. Exp Parasitol. 2014; 143: 55-59.
- 16Daryani A, Sharif M, Kalani H, Rafiei A, Kalani F, Ahmadpour E. Electrophoretic patterns of Toxoplasma gondii excreted/secreted antigens and their role in induction of the humoral immune response. Jundishapur J Microbiol. 2014; 7: e9525-e9531.
- 17Norouzpour Deilami K, Daryani A, Ahmadpour E, et al. Excretory-secretory antigens: a suitable candidate for immunization against ocular toxoplasmosis in a murine model. Comp Immunol Microbiol Infect Dis. 2014; 37: 369-374.
- 18Verma R, Khanna P. Development of Toxoplasma gondii vaccine: a global challenge. Hum Vaccin Immunother. 2013; 9: 291-293.
- 19Mercier C, Cesbron-Delauw M-F. Toxoplasma secretory granules: one population or more? Trends Parasitol. 2015; 31: 60-71.
- 20Nam H-W. GRA proteins of Toxoplasma gondii: maintenance of host-parasite interactions across the parasitophorous vacuolar membrane. Korean J Parasitol. 2009; 47: S29-S37.
- 21Sun X-M, Zou J, AA ES, et al. DNA vaccination with a gene encoding Toxoplasma gondii GRA6 induces partial protection against toxoplasmosis in BALB/c mice. Parasit Vectors. 2011; 4: 1.
- 22Jongert E, De Craeye S, Dewit J, Huygen K. GRA7 provides protective immunity in cocktail DNA vaccines against Toxoplasma gondii. Parasite Immunol. 2007; 29: 445-453.
- 23Rome ME, Beck JR, Turetzky JM, Webster P, Bradley PJ. Intervacuolar transport and unique topology of GRA14, a novel dense granule protein in Toxoplasma gondii. Infect Immun. 2008; 76: 4865-4875.
- 24Kalani H, Daryani A, Sharif M, et al. Comparison of eight cell-free media for maintenance of Toxoplasma gondii tachyzoites. Iran J Parasitol. 2016; 11: 104.
- 25Wang L, Lu G, Zhou A, et al. Evaluation of immune responses induced by rhoptry protein 5 and rhoptry protein 7 DNA vaccines against Toxoplasma gondii. Parasite Immunol. 2016; 38: 209-217.
- 26Cui YL, He SY, Xue MF, Zhang J, Wang HX, Yao Y. Protective effect of a multiantigenic DNA vaccine against Toxoplasma gondii with co-delivery of IL-12 in mice. Parasite Immunol. 2008; 30: 309-313.
- 27Hassan I, Wang S, Xu L, Yan R, Song X, XiangRui L. Immunological response and protection of mice immunized with plasmid encoding Toxoplasma gondii glycolytic enzyme malate dehydrogenase. Parasite Immunol. 2014; 36: 674-683.
- 28Desolme Bt, Mévélec M-N, Buzoni-Gatel D, Bout D. Induction of protective immunity against toxoplasmosis in mice by DNA immunization with a plasmid encoding Toxoplasma gondii GRA4 gene. Vaccine. 2000; 18: 2512-2521.
- 29Golkar M, Shokrgozar M-A, Rafati S, et al. Evaluation of protective effect of recombinant dense granule antigens GRA2 and GRA6 formulated in monophosphoryl lipid A (MPL) adjuvant against Toxoplasma chronic infection in mice. Vaccine. 2007; 25: 4301-4311.
- 30Dadimoghaddam Y, Daryani A, Sharif M, Ahmadpour E, Hossienikhah Z. Tissue tropism and parasite burden of Toxoplasma gondii RH strain in experimentally infected mice. Asian Pac J Trop Med. 2014; 7: 521-524.
- 31Bivas-Benita M, Laloup M, Versteyhe S, et al. Generation of Toxoplasma gondii GRA1 protein and DNA vaccine loaded chitosan particles: preparation, characterization, and preliminary in vivo studies. Int J Pharm. 2003; 266: 17-27.
- 32Martin V, Supanitsky A, Echeverria PC, et al. Recombinant GRA4 or ROP2 protein combined with alum or the Gra4 gene provides partial protection in chronic murine models of toxoplasmosis. Clin Diagn Lab Immunol. 2004; 11: 704-710.
- 33Altin JG, Parish CR. Liposomal vaccines—targeting the delivery of antigen. Methods. 2006; 40: 39-52.
- 34Munoz M, Liesenfeld O, Heimesaat MM. Immunology of Toxoplasma gondii. Immunol Rev. 2011; 240: 269-285.
- 35Correa D, Cañedo-Solares I, Ortiz-Alegría L, Caballero-Ortega H, Rico-Torres C. Congenital and acquired toxoplasmosis: diversity and role of antibodies in different compartments of the host. Parasite Immunol. 2007; 29: 651-660.
- 36David Sibley L. Invasion and intracellular survival by protozoan parasites. Immunol Rev. 2011; 240: 72-91.
- 37Denkers EY, Gazzinelli RT. Regulation and function of T-cell-mediated immunity during Toxoplasma gondii infection. Clin Microbiol Rev. 1998; 11: 569-588.
- 38Tighe H, Corr M, Roman M, Raz E. Gene vaccination: plasmid DNA is more than just a blueprint. Immunol Today. 1998; 19: 89-97.
- 39Sturge CR, Benson A, Raetz M, et al. TLR-independent neutrophil-derived IFN-γ is important for host resistance to intracellular pathogens. Proc Natl Acad Sci. 2013; 110: 10711-10716.
- 40EL-Malky MA, Al-Harthi SA, Mohamed RT, Bali MAE, Saudy NS. Vaccination with Toxoplasma lysate antigen and CpG oligodeoxynucleotides: comparison of immune responses in intranasal versus intramuscular administrations. Parasitol Res. 2014; 113: 2277-2284.
- 41Chen J, Li Z-Y, Huang S-Y, et al. Protective efficacy of Toxoplasma gondii calcium-dependent protein kinase 1 (TgCDPK1) adjuvated with recombinant IL-15 and IL-21 against experimental toxoplasmosis in mice. BMC Infect Dis. 2014; 14: 1.
- 42Xue M, He S, Zhang J, Cui Y, Yao Y, Wang H. Comparison of cholera toxin A2/B and murine interleukin-12 as adjuvants of Toxoplasma multi-antigenic SAG1-ROP2 DNA vaccine. Exp Parasitol. 2008; 119: 352-357.
- 43Glansbeek HL, Haagmans BL, te Lintelo EG, et al. Adverse effects of feline IL-12 during DNA vaccination against feline infectious peritonitis virus. J Gen Virol. 2002; 83: 1-10.
- 44Khosroshahi KH, Ghaffarifar F, Sharifi Z, et al. Comparing the effect of IL-12 genetic adjuvant and alum non-genetic adjuvant on the efficiency of the cocktail DNA vaccine containing plasmids encoding SAG-1 and ROP-2 of Toxoplasma gondii. Parasitol Res. 2012; 111: 403-411.
- 45Wu X-N, Lin J, Lin X, Chen J, Chen Z-L, Lin J-Y. Multicomponent DNA vaccine-encoding Toxoplasma gondii GRA1 and SAG1 primes: anti-Toxoplasma immune response in mice. Parasitol Res. 2012; 111: 2001-2009.
